Kisqali

Active Ingredient(s): Ribociclib
FDA Approved: * March 13, 2017
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

Ribociclib, sold under the brand name Kisqali and Kryxana marketed by Novartis,[1][2] is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer.[3] Ribociclib is a kinase inhibitor indicated in combination with: an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanc... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kisqali 200 mg Oral Tablet, Film Coated

NDC: 0078-0860

Labeler:

Novartis Pharmaceuticals Corporation

Kisqali 200 mg Oral Tablet, Film Coated

NDC: 0078-0867

Labeler:

Novartis Pharmaceuticals Corporation

Kisqali 200 mg Oral Tablet, Film Coated

NDC: 0078-0874

Labeler:

Novartis Pharmaceuticals Corporation